Effectiveness of a clinical decision support system for hypertension management in primary care: study protocol for a pragmatic cluster-randomized controlled trial

Jiali Song1, Xiuling Wang1, Bin Wang1, Yan Gao1, Jiamin Liu1, Haibo Zhang1, Xi Li1, Jing Li1, Ji-Guang Wang2, Jun Cai3, Jeph Herrin4, Jane Armitage5,6†, Harlan M. Krumholz2,7,8†, Xin Zheng1,9*† and on behalf of the LIGHT Collaborative Group

Abstract

Background: Clinical decision support systems (CDSS) are low-cost, scalable tools with the potential to improve guideline-based antihypertensive treatment in primary care, but their effectiveness needs to be tested, especially in low- and middle-income countries such as China.

Methods: The Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) trial is a pragmatic, four-stage, cluster-randomized trial conducted in 94 primary care sites in China. For each city-based stage, sites are randomly assigned to either implementation of the CDSS for hypertension management (which guides doctors' treatment recommendations based on measured blood pressure and patient characteristics), or usual care. Patients are enrolled during the first 3 months after site randomization and followed for 9 months. The primary outcome is the proportion of hypertension management visits at which guideline-based treatment is provided.

In a nested trial conducted within the CDSS, with the patient as the unit of randomization, the LIGHT-ACD trial, patients are randomized to receive different initial mono- or dual-antihypertensive therapy. The primary outcome of the LIGHT-ACD trial is the changes in blood pressure.

Discussion: The LIGHT trial will provide evidence on the effectiveness of a CDSS for improving guideline adherence for hypertension management in primary care in China. The nested trial, the LIGHT-ACD trial, will provide data on the effect of different initial antihypertensive regimens for blood pressure management in this setting.

Trial registration: ClinicalTrials.gov, identifier: LIGHT (NCT03636334) and LIGHT-ACD (NCT03587103). Registered on 3 July 2018.
Introduction
Hypertension is the leading modifiable risk factor for death globally [1]. Over the past decades, the number of individuals with hypertension is estimated to have increased by 90%, with the majority of the increase occurring in low- and middle-income countries (LMICs) [2]. In China, an estimated 244.5 million adults have hypertension, and only about 15% of these individuals have adequate blood pressure control, resulting in major health and economic burdens [3].

Improving the performance of primary care doctors, who play a key role in managing hypertension, and ensuring their adherence to guideline-recommended antihypertensive treatments are public health priorities in China [4]. Despite the decade-long efforts to strengthen the primary care system [5], the underuse of guideline-based antihypertensive treatments persists [6–8]. Moreover, given the substantial gaps in the licensing and education of primary care doctors [9], traditional strategies to empower their practices including educational training are resource-intensive to implement and may only yield modest effects [10]. A clinical decision support system (CDSS), characterized by generating recommendations through computerized algorithms, may circumvent these barriers to adequate management of hypertension [4, 11]. However, evidence of CDSS enhancing guideline adherent prescribing in hypertension is limited, especially in LMICs [12, 13]. Most studies have focused on assessing its effect on blood pressure reduction and have shown mixed results [14–16]. Understanding the effectiveness of CDSS for hypertension management in primary care could provide important information to develop effective strategies for mitigating the burden of hypertension in China and other LMICs.

In addition, in the course of testing the CDSS, there is an opportunity to test different antihypertensive regimens. Blood pressure guidelines endorse these antihypertensive therapies as equivalent even though there is a paucity of head-to-head comparisons [17, 18]. Using the CDSS to promote guideline adherence may facilitate such comparisons since randomization of treatment can be performed within the CDSS each time a decision support recommendation is generated for the patient. Nesting a randomized trial comparing antihypertensive regimens within CDSS will optimize the conduct and efficiency of the nested trial by streamlining the enrolment and follow-up.

Accordingly, our main aim is to conduct a cluster-randomized controlled trial, the Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) trial, to assess the effectiveness of a CDSS on improving guideline-concordant antihypertensive treatment and blood pressure control compared to usual care. Within the LIGHT trial, we also conduct a nested trial, the LIGHT-ACD trial, to compare blood pressure changes between different initial guideline-recommended drug regimens.

Methods
The LIGHT trial
Objectives
The primary objective of the LIGHT trial is to determine whether CDSS is effective in improving the use of guideline-based antihypertensive treatment compared to usual care, and the secondary objectives are to determine its effect on blood pressure changes and blood pressure control.

Trial design and setting
The LIGHT trial is a pragmatic, parallel-group, four-stage, cluster-randomized controlled trial assessing the effectiveness of CDSS in primary care in China, with primary care sites (including community health centers, community health stations, and township health centers) as the unit of randomization. In each stage, urban primary care sites are randomized to either implementation of the CDSS for hypertension management or usual care (Fig. 1). During the first 3 months after cluster randomization, patients who attend the clinic for hypertension management are screened for eligibility and if eligible asked to attend the clinic at least every 3 months with data collected at each visit (Fig. 2).

Eligibility criteria
In each city-based stage, local coordination centers of the trial invite all primary care sites in their network to participate in the trial. Primary care sites with hypertension clinics are eligible to be included if (1) at least one agent from each of the four classes of antihypertensive medication is available for the prescription [angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), beta-blockers, calcium channel blockers (CCB), diuretics]; (2) an electronic health record (EHR) is being used for hypertension management providing a structured template for collection of patient data; and (3) at least 100 patients with hypertension are routinely being seen. Cluster drop-out is not expected but might occur if sites voluntarily withdraw during the trial.
Fig. 1 Infrastructure of the LIGHT and LIGHT-ACD trials

Fig. 2 Schedule of enrollment, intervention allocation and assessment of the LIGHT trial using Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
Residents aged ≥18 years registered for hypertension treatment at the primary care sites are eligible for the LIGHT trial if they are taking 0–2 classes of antihypertensive medication. Major exclusion criteria include (1) history of coronary heart disease, heart failure, or chronic kidney disease; or (2) intolerance to 2 or more classes of antihypertensive medications; (3) systolic blood pressure (SBP) ≥180 mmHg or diastolic blood pressure (DBP) ≥110 mmHg at the screening visit (see detailed inclusion and exclusion criteria in Table 1). The screening of patients can be automatically performed by the customized EHR. As the informed consent for implementing the CDSS is waived in this trial, doctors can check the eligibility of all patients attending their clinics for hypertension management.

**Allocation**

Primary care sites selected are randomized to intervention or control arm (1:1 ratio) using computer-generated random numbers stratified by baseline appropriate antihypertensive treatment rate and site characteristics (see detailed stratifying factors for each stage in Supplement 1). Site randomization is performed centrally, and participating sites will be confirmed by local coordinating centers before randomization. The statistician assigns sites to the randomization strata and uses a computer program to randomly allocate half the sites in each strata to the intervention group; the remaining sites are allocated to the control group. Group allocation is unknown to any other team member before a formal announcement to the investigators and sites. Given the nature of the intervention, doctors and participants cannot be blinded.

Data analysts will follow a predefined analysis plan to avoid bias.

**Intervention**

The intervention consists of an EHR-based CDSS providing antihypertensive recommendations generated from information recorded at the visit. The recommendations are based on the Chinese primary care hypertension guidelines [19] but are generally consistent with international guidance [20, 21] and include treatment advice to add one or more of the 4 classes of medication at half or full dose (see an example of CDSS recommendation in Supplement 3). During prescribing, the dosages and frequencies of drugs can be filled in automatically according to the specific agents entered by doctors. To ensure that the intervention is being reliably delivered to doctors, clicking the icon for obtaining CDSS recommendations is designed to be mandatory before prescribing in the EHR. If the doctor decides not to follow the recommendation, a pop-up message stating “your prescription did not match with CDSS recommendation, please re-evaluate the classes/doses/frequencies of drugs.” and prescriptions can be modified accordingly. If the doctor decides not to follow the CDSS recommendation, relevant reasons (e.g., doctor preference or patient refusal) are recorded. In addition, if prescriptions involve contraindicated drugs, under-dosage, or over-dosage, a message warning is also triggered.

The CDSS algorithm was developed by clinicians in the research team based on guidelines for hypertension management [19–21]. After the algorithm was finalized, our information technology (IT) team

| Table 1 | Inclusion and exclusion criteria of participants for LIGHT and LIGHT-ACD trials |
|---------|-----------------------------------------------------------------------------|
| **Criteria** | **LIGHT** | **LIGHT-ACD** |
| **Inclusion** | Residents aged ≥ 18 years registered for hypertension treatment at primary care sites | Participants from intervention sites of LIGHT study with systolic blood pressure ≥ 140 mmHg at the screening visit |
| | Taking 0–2 classes of antihypertensive medications | Not taking antihypertensive medication or taking only one which was not beta-blocker |
| **Exclusion** | History of coronary heart disease*, heart failure, and chronic kidney disease | Known/diagnosed diabetes mellitus |
| | Intolerance to 2 or more classes of antihypertensive medications | Intolerance to 1 or more classes of antihypertensive medications |
| | Secondary hypertension (physician-diagnosed) | Home blood pressure (if available) below 135/85 mmHg |
| | Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at the screening visit | |
| | Serious medical conditions (e.g., malignant cancer and hepatic dysfunction) | |
| | Currently in an acute episode of disease | |
| | Currently pregnant or breastfeeding, or planning a pregnant or breastfeeding during the study | |
| | Cognitive or communication disorders | |
| | Including angina, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, >50% stenosis of coronary artery, or positive stress test | |

* including angina, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, >50% stenosis of coronary artery, or positive stress test
translated it into computational logic. The logic of the CDSS was tested using simulated patient data to trigger each possibility. The CDSS was further validated by comparing the treatment recommendations provided by CDSS with that by clinicians for specific test cases. The IT team was notified when any discrepancies were found so that the programming errors could be identified. This process was repeated until no errors were observed in all test cases. The CDSS was piloted in two excluded sites. During the pilot test, there were a total of 78 hypertension visits. The mean SBP and DBP were 131.5 mmHg and 76.6 mmHg, respectively. Doctors followed the CDSS recommendations in 52.6% of hypertension visits. The most common reason for the non-compliance was patient refusal to follow even though such recommendations had been provided by doctors in the shared decision process (83.8%).

After randomization, doctors in the intervention sites receive face-to-face or online training on the use and interpretation of the CDSS output. In addition, the evidence base of the output is briefly introduced. After the training, the IT team releases a new version of EHR with CDSS available for the intervention sites, doctors are instructed to use the CDSS directly in all hypertension visits thereafter.

**Control**

In control sites, the EHR is used to record the same information, but no antihypertensive recommendation is made. Prescribing decisions are made by doctors based on their knowledge and usual practice.

**Outcomes**

The primary outcome for the LIGHT trial is the proportion of hypertension visits (see Supplement 2 for specification) during which appropriate antihypertensive treatment is prescribed. Appropriate antihypertensive treatment is defined as a prescription compliant with the pre-specified guideline-based recommendations (see Supplement 4 for specifications). The secondary outcomes include the average change in systolic blood pressure, the proportion of those whose blood pressure is controlled at 9 months, and the proportion of hypertension visits with acceptable antihypertensive treatment, which is defined as either appropriate antihypertensive treatment (as above) or those treatments with acceptable reasons for failing to titrate antihypertensive treatment. An exploratory outcome is the number of patients experiencing a vascular event defined as a composite of cardiac death, non-fatal stroke, and non-fatal myocardial infarction (Table 2).

**Data collection and management**

To improve the workflow, patient data are collected via the customized EHR, which only collects information necessary for hypertension pharmacological management (Table 3). The EHR performs built-in data checks to verify that the data are complete and meet predefined data ranges and formats. Blood pressure is measured with a validated automated sphygmomanometer (Omron HBP-1300) [22], after at least a 5-min rest in the sitting position. Two blood pressure readings are taken 1–2 min apart, and the average value is recorded. Trained primary care doctors (with the assistance of other trained providers at some sites) are responsible for participant

---

**Table 2 Outcomes of LIGHT and LIGHT-ACD trials**

| Outcomes       | LIGHT                              | LIGHT-ACD                                                                 |
|----------------|------------------------------------|---------------------------------------------------------------------------|
| Primary        | Appropriate (guideline-based) antihypertensive treatment rate | Absolute change in blood pressure at 9 months of different regimens of initial therapy |
| Secondary      | Absolute change of systolic blood pressure at 9 months        | Proportion of individuals with blood pressure controlled (SBP <140 mmHg and DBP <90 mmHg) at 9 months |
|                | Blood pressure control rate (defined as SBP <140 mmHg and DBP <90 mmHg) at 9 months | Proportion of individuals with SBP <160 mmHg and DBP <100 mmHg at 9 months |
|                | Acceptable (appropriate/non-appropriate but with proper reasons) antihypertensive treatment rate | Proportion of individuals who received monotherapy*, dual therapy, triple therapy, and referral at 9 months |
| Exploratory    | A composite of cardiac death, non-fatal stroke, and non-fatal myocardial infarction | Proportion of individuals with antihypertensive drug side-effects |
|                |                                                                  | Proportion of individuals transferred to usual care for any reason |
|                |                                                                  | Absolute change in blood pressure at 9 months of different protocols* |

* Only assessed in Population 1, who are not currently taking any antihypertensive medication with systolic blood pressure 140–159 mmHg, and initiated with monotherapy
enrolment and follow-up. After enrolment, eligible participants are asked to attend the clinic at least every 3 months for follow-up. As we include participants registered for hypertension treatment at the primary care site in this trial, a substantial proportion of them are expected to be retained. To maximize the retention of participants, they will also be contacted and invited to attend the clinics for collecting data during follow-up.

All data are securely transmitted to the central server through automatic electronic transfer and securely stored in an encrypted and password-protected database. Data confidentiality policies on data collection, storage, and analysis have been strictly imposed to ensure the confidentiality of personal information.

**Data monitoring and quality control**

The Trial Steering Committee periodically reviews trial progress and provides advice to the investigators on all aspects of the trial. No interim analyses of intervention effectiveness are planned. Due to the low-risk nature of the trial, a Data Monitoring Committee is not necessary. Similarly, there are no anticipated adverse events and harms from the trial intervention. Any unanticipated problems and adverse events will be reported to the research team and appropriate regulatory bodies.

We randomly select blood pressure values recorded in EHR daily (at least one value per site) and check against the recordings in the automated sphygmomanometer. We also compare the prescription recorded in the EHR with paper/electronic prescription sheets to verify their consistency biweekly. A bespoke website was developed for the research team to monitor the progress and quality of the trial in real time. Through this website, we can review the comparison results of blood pressure values in EHR and sphygmomanometer to monitor the accuracy of documentation in all sites, and any data with invalid values can be searched and traceable corrected. CDSS recommendations can be also viewed via the website to ensure that the CDSS is working as designed. In addition, on-site audits are regularly conducted by the research team to verify that data are generated, documented, and reported in compliance with the protocol.

**Sample size**

As this is a staged pragmatic trial, we have the capacity to add sites as the trial progresses. Initial statistical power was based on the number of sites potentially eligible in stage 1 at the time the power analysis was being conducted; thus, we assumed that at least 10 primary care sites would be randomized to the intervention arm and 10 to the control arm, the baseline appropriate treatment rate would be 55% with maximum type I error of $\alpha = 0.05$, a moderate intra-site correlation of 0.05, a within-patient correlation of 0.1, and statistical power of 90%, and we needed 3 hypertension visits per patient for 50 patients at each site to detect an 18% absolute difference in the appropriate treatment rate between the two arms. Subsequent enrolment increased the number of participating sites to 94, randomized in 4 stages; under the same assumptions as above, we anticipate that the final sample will provide 90% power to detect a true difference of 4% in the appropriate treatment rate. This difference is close to the average effect of CDSS in improving the process of care in prior studies [23, 24].
Statistical analysis
The analyses and reporting of the results will follow the Consolidated Standards of Reporting Trials guidelines for cluster-randomized controlled trials [25]. All the analyses will be performed on an intention-to-treat basis. Multiple imputations by chained equations will be used to account for missing values.

With all comparative outcomes, we will use mixed-effects generalized linear regression models, using logistic or linear response for dichotomous or continuous outcomes, respectively, and including a random effect for the study site. Implementation stages will be treated as strata, with adjustment for calendar time to account for secular trends. The consistency of treatment effects on the primary outcome will be explored in predefined subgroups, including age, gender, education, implementation stage, tertiles of baseline cluster-level appropriate treatment rate, blood pressure level, and use of antihypertensive medications. All statistical tests will be performed using 2-sided tests at the 0.05 level of significance, but the number of tests and \( p \)-value will be taken into account in the interpretation of the results.

The LIGHT-ACD trial
Objectives
The primary and secondary objectives of the LIGHT-ACD trial are to compare blood pressure changes and blood pressure control between different initial antihypertensive regimens, respectively.

Trial design and setting
The LIGHT-ACD trial is an individually randomized trial conducted in the intervention sites of the LIGHT trial. In this nested trial, patients are randomized to receive various initial antihypertensive therapies, and blood pressure changes/control rates between different regimens are compared (Fig. 1).

Recruitment of patients
The patients at the intervention sites of the LIGHT trial are eligible if they have a measured baseline SBP \( \geq 140 \) mmHg and are taking 0–1 class of antihypertensive medication. Key exclusion criteria include diabetes mellitus and intolerance to at least one of the four classes of antihypertensive medications (Table 1). The eligible patients in the LIGHT-ACD trial are categorized into 2 subpopulations. Patients with an SBP of 140–159 mmHg who are not taking any antihypertensive medication are categorized as Population 1, the remainder as Population 2.

Randomization and blinding
Populations 1 and 2 are randomized to different antihypertensive regimens separately. Minimization randomization [26] is used to ensure the balancing of age, gender, and education level among different arms. The allocation is centrally performed and concealed within the CDSS. Neither doctors nor patients are blinded to treatment allocation. Population 1 individuals are randomized to receive one of the initial monotherapies of A (ACEI or ARB), C (CCB), or D (diuretics). If additional treatment is needed, they are further randomized to add either C or D, so patients initiated with A follow either A-AC-ACD or A-AD-ADC with C and D as the add-on medications, respectively. The randomization of drug regimen among patients initiated with C or D is similar to patients initiated with A. Population 2 individuals are randomized to receive one of the three initial dual therapies of AC, AD, or CD. Subsequently, D, C, or A are added to achieve blood pressure control, if necessary, respectively (Fig. 1).

Treatments
The assignment of treatment is presented as the CDSS recommendation (class and dose). The specific agent within each class is at the doctor’s discretion based on the available medications of the sites. For each case, the titration of antihypertensive medication is performed automatically by the CDSS according to the assigned drug regimen.

Outcomes
The primary outcome is the difference in the change in blood pressure from baseline to 9 months between different drug regimens of initial therapy. Secondary outcomes include the proportion of individuals with blood pressure controlled at 9 months; the proportion of individuals with SBP <160 mmHg and DBP <100 mmHg at 9 months; the proportion of individuals who received monotherapy (only in Population 1), dual therapy, triple therapy, and referral at 9 months; the proportion of individuals reported to have antihypertensive drug-related side-effects; and the proportion of individuals transferred to usual care for any reasons. The exploratory outcome is the change in blood pressure from baseline to 9 months of six protocols embedded in the CDSS (Table 2).

Sample size
We assume approximately 25% of the LIGHT intervention patients are in Population 1 and 75% in Population 2, with an 80% follow-up rate for the primary outcome. We used estimates from the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) for power calculations [18, 27]. For each population, we estimate the detectable difference in SBP between treatment groups across a similar range of the intervention participants and statistical power. We assume that the
standard deviation in SBP is \( \sigma = 10 \) mmHg and that the within-patient SBP correlation is \( R^2 = 0.2 \) with a maximum type I error that is Sidak-corrected for three comparisons, \( \alpha = 0.017 \) [28]. With the current number of LIGHT sites, we estimate about 2100 eligible LIGHT-ACD participants overall with complete follow-up. Under these assumptions, we estimate that for the comparisons of initial monotherapies of A, C, and D in Population 1, we will have 80% power to detect a difference of 3.5 mmHg in SBP, and for comparisons of dual therapies of AC, AD, and CD in Population 2, we have 80% power to detect a difference of 2 mmHg in SBP.

**Statistical analysis**

All the intervention evaluations will be performed on an intention-to-treat basis. Multiple imputations by chained equations will be used to account for missing values.

Patient characteristics will be summarized by comparison group and tested for differences using t-tests and chi-square tests. To assess the effectiveness of each initial antihypertensive regimen and protocol, we will estimate a mixed-effects generalized linear model for each outcome including indicators for treatment groups, baseline blood pressure, and imbalanced patient characteristics. Additionally, we will perform pre-specified subgroup analyses of outcomes by age, sex, education, smoking status, and tertiles of baseline blood pressure. Considering potential crossovers among treatments, we will also assess the heterogeneity of the treatment effect among per-protocol populations.

**Discussion**

The LIGHT trial is, to the best of our knowledge, the largest pragmatic randomized trial exploring the feasibility and effectiveness of a decision support tool to deliver high-quality care for hypertension in primary care. Moreover, by adopting a streamlined study design, we have nested a patient-level randomized trial (LIGHT-ACD trial) into this cluster-randomized trial using an algorithm-based CDSS tool.

Our studies have several potential strengths. First, we have developed a usable CDSS, which can easily be integrated into the routine clinical workflow and provides tailored antihypertensive recommendations at the point of care. These features are highly correlated with the effectiveness of CDSS for improving the process of care and patient outcomes [23, 29, 30]. As recommendations of CDSS are generated automatically by the built-in algorithm, which is developed based on current guidelines, this approach can assist primary care doctors, even those with less training, in making informed and evidence-based prescribing decisions.

Second, we have built a streamlined framework for a clinical trial that enabled us to compare the effectiveness of several guideline-based initial antihypertensive regimens. Earlier randomized clinical trials such as the ALLHAT [18] and ACCOMPLISH [31] trials provided a direct comparison among several monotherapies or dual therapies. These trials are not contemporary and did not include large Asian populations, so there remain gaps in knowledge. In contrast with these standalone trials, the conduct of the LIGHT-ACD trial is embedded into the existing framework of the LIGHT trial. We incorporate a series of stepped treatment protocols into the CDSS, whereby the random allocation of recommended medication can be performed automatically by following the algorithm-consistent order at each encounter where decision support is delivered [32]. While assessing the effectiveness of CDSS, the effectiveness of common initial antihypertensive monotherapies or dual therapies can be compared unobtrusively [31, 33–35].

Third, the pragmatic design of both trials enables us to demonstrate the real-world effectiveness of intervention/treatment with greater external validity [36, 37]. In contrast to trials with study-specific visits, the enrolment and follow-up of patients, and the collection of outcome data in our trial are incorporated into routine clinical practice. Furthermore, the exclusion criteria are kept to a minimum to enroll a diverse spectrum of the population. These considerations improve the efficiency of trials and enhance the generalizability of the study results [37].

Fourth, the two studies are further distinguished by the efforts to build a learning decision support tool. Although the algorithm of CDSS is kept consistent during the four stages of the trial, it has the potential to be adaptively updated after the results of the LIGHT-ACD trial are available. For the ultimate implementation of the CDSS, the tool could continuously generate new knowledge in terms of the effectiveness of treatment strategies from the ongoing delivery of care, whereby the CDSS could be iteratively tested and improved by shifting the randomization ratio of stepped antihypertensive protocols toward the more effective group [38].

Our study has some potential limitations. First, the outcomes are focused on surrogate outcomes and not clinical outcomes such as cardiovascular events. To examine the effect on clinical events, a much longer trial would be required. However, it is expected that improvements in blood pressure control over time would favorably affect clinical outcomes. Second, given the nature of the CDSS, which delivers its recommendation directly to doctors, blinding was not feasible. We minimized the potential bias by using objective measures as primary and secondary outcomes. Third, due to the limited timeframe of the study, an extended follow-up was not included following...
the intervention to measure the persistence of effects after the intervention ceases. Fourth, we did not include consideration of diet, in part because of issues of the validity of self-reporting. In this trial, we only collected information necessary for pharmacological hypertension management such as the blood pressure measurements, comorbidities, current medications, and prescriptions. However, the confounding effect of diet may have been minimized through site randomization.

In conclusion, both trials should be able to provide useful evidence regarding the effectiveness of this decision support tool on improving adherence to guidelines for hypertension management in primary care, and on the comparative effectiveness of different initial antihypertensive regimens for blood pressure reduction in the real-world setting.

Trial status
Protocol version 4.4 commenced on December 28, 2020. As of May 2021, 94 sites (including 7,656 patients in LIGHT and 494 participants in the LIGHT-ACD trial) have been randomized in 4 stages. Site randomization of Stage 1 was on 21 August 2019, Stage 2 on 4 December 2019, Stage 3 on 1 March 2021, and Stage 4 on 14 April 2021. The implementation of the trial is affected by the outbreak of COVID-19, we have extended the enrolment and follow-up periods appropriately in each stage of the trial. Currently, all sites will complete follow-up by the middle of 2022.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13063-022-06374-x.

Additional file 1: Supplement 1. Stratification factors for each stage in site randomization of LIGHT trial.
Additional file 2: Supplement 2. Specification of hypertension visits.
Additional file 3: Supplement 3. Example of CDSS recommendation.
Additional file 4: Supplement 4. Specifications of guideline-based antihypertensive treatment.
Additional file 5: Supplement 5. Trial registration data of the LIGHT trial.
Additional file 6: Supplement 6. Trial registration data of the LIGHT-ACD trial.

Acknowledgements
We appreciate the steering committee member of the study: Robert Clarke from University of Oxford, Sharon-Lise T. Normand from the Harvard T.H. Chan School of Public Health, Frederick A. Masoudi from University of Colorado School of Medicine, Songtao Tang from the Community Health Center of Liaobu County, Wenchun Ma from the Fuwai Hospital, and Jian Xu from the Center for Chronic Disease Control of Shenzhen for their support and advice. We thank Lawrence J. Fine and George A. Mensah from National Institutes of Health for their contributions in study design. We appreciate the multiple contributions made by study teams at the National Clinical Research Center for Cardiovascular Diseases in the realms of study design and operation, particularly site management and coordination by Bo Gu, Yilan Ge, Fuyu Jing, Lei Bi, Huijun Jin, Teng Li, and Liyuan Sui, and IT development and maintenance by Shuyang Hua and Mengnan Zhu. We thank the local sites in the collaborative network for their support and data collection.

Dissemination plans
The results of this study will be presented at symposia and conferences and published in scientific journals.

Authors’ contributions
HMK, JA, and XZ designed the study. XZ acted as the principal investigator to take responsibility for all respect for the study. JS, HMK, JA, and XZ conceived of this article. JS wrote the manuscript with further contributions from XZ, JA, HMK, JH, JW, JC, JL, XL, HZ, JL, BW, XW, and YG. JH calculated the sample size and provided advice in the randomization method of the study. YG performed daily data monitoring and completed all the statistical analyses. XZ, LJ, HZ, JS, XW, and BW developed the algorithm of the CDSS. All authors contributed to critical revisions and approved the final version of the article.

Funding
This project was supported by the CAMS Innovation Fund for Medical Science (2016‑I2M‑1‑006), the CAMS Fund for Clinical and Translational Research (2021‑I2M‑C&T‑B‑031), the Sanming Project of Medicine in Shenzhen (SZSM201811093), and the 111 Project from the Ministry of Education of China (B16005). These fundings have no role in the design of the study, collection, analysis, interpretation of data, or in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study will be available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The ethics committee of Fuwai Hospital approved both trials. All sites accepted this ethics approval or obtained local approval by internal ethics committees as appropriate. Given that guideline-based recommendations provided by CDSS was considered to have minimal risk for the patients, informed consent for implementing the CDSS in both trials is waived. A simple written informed consent for participants was acquired to send a text message as a brief medical record (e.g., blood pressure, prescriptions, and follow-up reminders) after each visit. Any substantial amendments to the protocol or the consent materials will be approved by relevant ethical review bodies. Since there are no harms to be expected resulting specifically from the trial-specific interventions, no special provisions are made for trial-specific ancillary or post-trial care.

Competing interests
In the past three years, Dr. Harlan Krumholz received expenses and/or personal fees from UnitedHealth, Element Science, Artena, Reality Labs, Tesseract/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, and Martin/Baugham Law Firm. He is a co-founder of Refactor Health and HugoHealth, and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services and through Yale University from Johnson & Johnson. Dr. Jing Li discloses that she is a recipient of research grants from the government of China, through Fuwai Hospital; for research to improve the management of hypertension and blood lipids, and to improve care quality and patient outcomes of cardiovascular disease; is a recipient of research agreements with Amgen, through National Center for Cardiovascular Diseases (NCCD); and the government of China, through Fuwai Hospital; for research to improve the management of hypertension and blood lipids, and to improve care quality and patient outcomes of cardiovascular disease; is a recipient of research grants from the government of China, through Fuwai Hospital; and is associated with contracts, through Tesseract/4Catalyst, F-Prime, and the Siegfried and Jensen Law Firm, and Arnold and Porter Law Firm.

Author details
1National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, National Center

Page 9 of 11
for Cardiovascular Diseases, 167 Beilishi Road, Beijing 100037, China. 2 The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 3 Hypertension Center, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China. 4 Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. 5 Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. 6 MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. 7 Center for Outcome Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA. 8 Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA. 9 National Clinical Research Center for Cardiovascular Diseases, Shenzhen, Coronary Artery Disease Center, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, China.

Received: 27 June 2021 Accepted: 29 April 2022 Published online: 16 May 2022

References
1. Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392(10159):1923–94. https://doi.org/10.1016/S0140-6736(18)32225-6.
2. Zhou B, Bentham J, Cesare Mariachiara D, et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389(10064):37–55. https://doi.org/10.1016/S0140-6736(16)31919-5.
3. Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China. Circulation. 2018;137(22):2344–56. https://doi.org/10.1161/CIRCULATIONAHA.117.032380.
4. Li X, Krumholz HM, Yip W, et al. Quality of primary health care in China: challenges and recommendations. Lancet. 2020;395(10239):1802–12. https://doi.org/10.1016/S0140-6736(20)30122-7.
5. Chen Z. Launch of the health-care reform plan in China. Lancet (London, England). 2009;373(9672):1322.
6. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet (London, England). 2017;390(10112):2549.
7. Su M, Zhang Q, Bai X, et al. Availability, cost, and prescription patterns of antihypertensive medications in primary healthcare in China: a nationwide cross-sectional survey. Lancet (London, England). 2017;390(10112):2559–68. https://doi.org/10.1016/S0140-6736(17)32476-5.
8. Gu H, Li W, Yang J, Wang Y, Bo J, Liu L. Hypertension prevalence, awareness, treatment and control among Han and four ethnic minorities (Uygur, Hui, Mongolian and Dai) in China. J Hum Hypertens. 2015;29(9):553–60. https://doi.org/10.1038/jhh.2014.123.
9. Li X, Lu J, Hu S, et al. Primary health-care system in China. Lancet (London, England). 2017;390(10112):2584.
10. Rowe AK, Rowe SY, Peters DH, Holloway KA, Chalker J, Ross-Degnan D. Effectiveness of strategies to improve health-care provider practices in low-income and middle-income countries: a systematic review. Lancet Glob Health. 2018;6(11):e163–75. https://doi.org/10.1016/s2214-109x(18)30398-x.
11. Liang W, Birns CW, Lee AH. Computerised clinical decision support in rural China. Lancet. 2009;373(9657):30. https://doi.org/10.1016/S0140-6736(08)61955-8.
12. Roshanov PS, Misra S, Gerstein HC, et al. Computerized clinical decision support systems for chronic disease management: a decision-maker-researcher partnership systematic review. Implement Sci. 2011;6(1):1–16.
13. Anchala R, Pinto MR, Shroff A, et al. The role of Decision Support System (DSS) in prevention of cardiovascular disease: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47064. https://doi.org/10.1371/journal.pone.0047064.
14. Anchala R, Kappoge S, Pant H, Di Angelantonio E, Franco OH, Prabhakaran D. Evaluation of effectiveness and cost-effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial. J Am Heart Assoc. 2015;4(1):e001213. https://doi.org/10.1161/jaha.114.001213.
15. Prabhakaran D, Jha D, Prieto-Merino D, et al. Effectiveness of an mHealth-based electronic decision support system for integrated management of chronic conditions in primary care. Circulation. 2019;139(3):380–91. https://doi.org/10.1161/circulationaha.118.038192.
16. Groenholm TKJ, Asselbergs FW, Groenwold RH, Grobbee DE, Visseren FLJ, Bots ML. The effect of computerized decision support systems on cardiovascular risk factors: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2019;19(1):9. https://doi.org/10.1186/s12911-019-0824-x.
17. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.cd001841.pub3.
18. The Allhat O, Coordinators for the Allhat Collaborative Research G. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97. https://doi.org/10.1001/jama.288.23.2981.
19. Office for Management of Hypertension in Primary Care NEPHSP. National Hypertension Prevention and Management Guidelines for Primary Health Care. Chin Circ J. 2017;11.
20. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ABC/ACPM/AGPA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex : 1979). 2017;71(6):1269–524. https://doi.org/10.1161/01.hyp.0000500000000066.
21. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report of the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. https://doi.org/10.1001/jama.2013.284427.
22. Meng L, Zhao D, Pan Y, Ding W, Wei Q Li H, Gao P, Li J. Validation of Omron HBP-130 professional blood pressure monitor based on auscultation in children and adults. BMC Cardiovasc Disord. 2016;16:9. https://doi.org/10.1186/s12872-015-0177-2.
23. Kwan JL, Lo L, Ferguson J, et al. Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials. BMJ (Clinical research ed). 2020;362:m3216. https://doi.org/10.1136/bmj.m3216.
24. Shojania KG, Jennings A, Mayhew A, Ramsay C, Eccles M, Grimshaw J. Effect of point-of-care computer reminders on physician behaviour: a systematic review. Cmaj. 2010;182(5):E216–25. https://doi.org/10.1503/cmaj.090578.
25. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. Bmj. 2012;345:e5661. https://doi.org/10.1136/bmj.e5661.
26. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103–15.
27. Shahu A, Herrin J, Dhrusa SS, et al. Disparities in socioeconomic context and association with blood pressure control and cardiovascular outcomes in ALLHAT. J Am Heart Assoc. 2019;8(15). https://doi.org/10.1161/ jaha.119.012277.
28. ZK. S. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967;62(321):626–33.
29. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ. 2005;330(7494):626–33. https://doi.org/10.1136/bmj.330.7494.626.
30. Jameson K, Weber MA, Bakiri GI, et al. Benzeprol plus amlopidine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28. https://doi.org/10.1056/nejmoa0806182.
32. Frieden TR, King SMC, Wright JS. Protocol-Based Treatment of Hypertension. JAMA. 2014;311(1):21. https://doi.org/10.1001/jama.2013.282615.

33. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394(10211):1816–26. https://doi.org/10.1016/S0140-6736(19)32317-7.

34. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–31. https://doi.org/10.1016/S0140-6736(04)16451-9.

35. Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649–59. https://doi.org/10.1097/HJH.0b013e328348345d.

36. Ford I, Norrie J. Pragmatic Trials. N Engl J Med. 2016;375(5):454–63. https://doi.org/10.1056/NEJMra1510059.

37. Mentz RJ, Hernandez AF, Berdan LG, et al. Good Clinical Practice Guidance and Pragmatic Clinical Trials. Circulation. 2016;133(9):872–80. https://doi.org/10.1161/CIRCULATIONAHA.115.019902.

38. Horwitz LI, Kuznetsova M, Jones SA. Creating a Learning Health System through Rapid-Cycle, Randomized Testing. N Engl J Med. 2019;381(12):1175–9. https://doi.org/10.1056/NEJMsa1900856.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.